# Repatha (evolocumab) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/evolocumab

> The FDA approved Repatha (evolocumab), sponsored by AMGEN INC (AMGN), on February 26, 2021.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | Repatha (evolocumab) |
| Codes | AMG-145 |
| Sponsor | AMGEN INC (AMGN) https://sec-api.dev/companies/amgn/catalysts |
| Indications | [Coronary Heart Disease (CHD)](https://sec-api.dev/indications/coronary-heart-disease-chd) |
| Modality | biologic |
| FDA designations | none disclosed |

## Timeline

### August 27, 2015: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed the review of BLA 125522/Original 2, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22125522Orig2s000OtherActionLtrs.pdf%22

### February 26, 2021: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125522 ORIG-2 (Efficacy): submission_status AP, submission_status_date 20210226, review_priority STANDARD; sponsor_name AMGEN INC; product REPATHA (EVOLOCUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125522%22

### September 24, 2021: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125522 SUPPL-29 (Efficacy): submission_status AP, submission_status_date 20210924, review_priority STANDARD; sponsor_name AMGEN INC; product REPATHA (EVOLOCUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125522%22

### July 25, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Coronary Heart Disease (CHD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03872401 (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-06-25." https://clinicaltrials.gov/study/NCT03872401

### June 25, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Coronary Heart Disease (CHD).
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03872401 (Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-25 (ACTUAL); Lead Sponsor Amgen; Results First Posted 2026-06-25." https://clinicaltrials.gov/study/NCT03872401?tab=results

### October 9, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125522 SUPPL-47 (Efficacy): submission_status AP, submission_status_date 20261009, review_priority STANDARD; sponsor_name AMGEN INC; product REPATHA (EVOLOCUMAB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125522%22

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/evolocumab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Repatha (evolocumab) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/evolocumab

```bibtex
@misc{secapidev_pdufa_evolocumab_20261116,
  title        = {Repatha (evolocumab) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/evolocumab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_evolocumab_20261116","title":"Repatha (evolocumab) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/evolocumab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
